Synopsis: A small-cap pharmaceutical manufacturer saw brisk buying interest as its stock advanced sharply, with market participants positioning ahead of the record date fixed for a 2:1 bonus share issue approved earlier by shareholders at the company’s annual general meeting.
Bonus issues tend to draw renewed attention to smaller listed names, and this week’s move in a Mumbai-based pharmaceutical manufacturer fits that pattern. Investors have been tracking the counter closely ahead of a corporate action that will expand their shareholding without any additional investment. With the record date now formally fixed, focus shifts to what a larger equity base could mean for the company going forward.
With a market capitalisation of Rs.1,509 Crores, shares of Fredun Pharmaceuticals Ltd. are trading at Rs.2,733 per share, i.e.5.79% above its previous closing price of Rs.2,583.35. It has a P/E ratio of 36.69.
Board Fixes Record Date for 2:1 Bonus Issue
Fredun Pharmaceuticals Limited has fixed 16th July 2026 as the record date for determining shareholder entitlement to bonus equity shares in the ratio of 2:1. This means eligible shareholders will receive two fully paid-up equity shares of ₹10 each for every one existing share of ₹10 held, effectively tripling their shareholding without any cash outflow.
The bonus issue was approved by shareholders at the company’s Annual General Meeting held on 30th June 2026. The new shares will rank pari passu with existing equity shares in all respects, including dividend entitlement and other corporate benefits.
The company has also arranged for a corresponding adjustment to the conversion ratio of its outstanding warrants, ensuring warrant holders receive an economic benefit equivalent to what they would have gotten had their warrants been converted into shares before the record date.
Financial Performance Backing the Corporate Action
On a consolidated basis, the company’s FY26 (year ended March 2026) numbers show healthy improvement over FY25. Revenue rose to Rs 635 crore from Rs 454 crore, translating to growth of roughly 40% year-on-year. Operating profit climbed to Rs 91 crore from Rs 52 crore, with operating margins expanding to 14% from 12%.
Net profit for the year came in at Rs 33 crore against Rs 20 crore a year earlier, an increase of close to 65% on a calculated basis, while earnings per share improved to Rs 59.60 from Rs 41.81. Interest costs and depreciation both rose alongside the scale-up in operations, and the effective tax rate ticked up to 31% from 28%.
Quarter-wise, the fourth quarter of FY26 was the strongest of the year on the revenue front, with sales of Rs 213 crore, while net profit for the quarter stood at Rs 11 crore, continuing a steady sequential improvement seen through the year.
About the Company
Fredun Pharmaceuticals Limited is a Mumbai-headquartered pharmaceutical company with a manufacturing facility located in Vevoor, Palghar. Incorporated in 1987, the company operates under the CIN L24239MH1987PLC043662 and is listed on BSE under scrip code 539730. It is engaged in the manufacture and marketing of pharmaceutical formulations under its “Compassionate Healthcare” positioning, catering to both domestic and international markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
